[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-gastroesophageal-junction-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-gastroesophageal-junction-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,68,93,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100576918","robotic-versus-laparoscopic-radical-surgery-for-locally-advanced-gastric-cancer-100576918",false,"NCT06791538","Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer","A Multicenter, Prospective, Randomized Controlled Clinical Study of Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Age \\> 18 years and \\\u003C 75 years.\n2. Primary gastric lesion histologically confirmed as gastric adenocarcinoma (including papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, poorly differentiated adenocarcinoma, etc.) via endoscopic biopsy.\n3. Preoperative clinical staging as locally advanced gastric cancer (cT2-4a, N0-3, M0) according to the 8th edition of the AJCC TNM staging system.\n4. No distant metastasis on preoperative examination, and no direct invasion of the pancreas, spleen, or other adjacent organs.\n5. Preoperative ECOG performance status score of 0 or 1.\n6. Preoperative ASA (American Society of Anesthesiologists) physical status score of I-III.\n7. Consent to participate in the study and signing of the informed consent form.\n\nExclusion Criteria:\n\n1. Previous history of gastric malignancy surgery, including submucosal resection and\u002For endoscopic mucosal resection.\n2. History of upper abdominal surgery (excluding laparoscopic cholecystectomy).\n3. Preoperative imaging shows regional lymph nodes with confluent enlargement (maximum diameter ≥3cm).\n4. Patient underwent emergency surgery due to gastric tumor bleeding or perforation.\n5. History of other malignancies, or presence of other malignant tumors detected during preoperative examination.\n6. Patient has a history of malignant tumor, or other malignant tumors were found during preoperative examination\n7. ASA (American Society of Anesthesiologists) score \\>3.\n8. Severe psychiatric disorders.\n9. History of unstable angina or myocardial infarction within the past 6 months.\n10. History of cerebral infarction or cerebral hemorrhage within the past 6 months.\n11. Severe pulmonary disease with FEV1 \\\u003C 50%.\n12. Systemic corticosteroid therapy within 1 month prior to the study.\n13. Need for concurrent surgery for other diseases.\n14. Pregnant or breastfeeding women.","ALL","18 Years","75 Years",{"count":20,"type":21},740,"ESTIMATED","INTERVENTIONAL",[24],"NA","This \\[Study Type: Clinical Trial\\] aims to \\[Primary Objective: evaluate the long-term efficacy and safety of robotic gastrectomy for locally advanced gastric cancer\\] in \\[Participant Population: patients with locally advanced gastric cancer, aged \\>18 years and \\\u003C75 years\\]. The primary questions it seeks to answer are:\n\nIs the 3-year disease-free survival rate of robotic gastrectomy non-inferior to that of laparoscopic gastrectomy? Is the perioperative safety of robotic gastrectomy superior to that of laparoscopic gastrectomy? Researchers will compare \\[Intervention Groups: Robotic Gastrectomy vs. Laparoscopic Gastrectomy\\] to determine whether \\[robotic surgery offers advantages in long-term efficacy and perioperative safety\\].\n\nParticipants will:\n\nSign an informed consent form and be randomly assigned to either the robotic surgery group or the laparoscopic surgery group.\n\nUndergo the assigned surgical procedure and receive regular follow-up visits (at 30 days, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 2 years, 2.5 years, and 3 years postoperatively).\n\nComplete physical examinations, blood tests (including complete blood count, biochemical markers, and tumor markers), and imaging studies (such as abdominal CT, upper gastrointestinal endoscopy, and chest X-ray) during the follow-up period.",[27],"Gastric Cancer, Gastroesophageal Junction Cancer",[29,30],"Robotic Gastrectomy","Laparoscopic Gastrectomy","RECRUITING","2025-06-05",{"date":34,"type":35},"2025-06-08","ACTUAL",{"date":37,"type":35},"2025-02-01",{"date":39,"type":21},"2028-02-01",{"name":41,"class":42},"Southwest Hospital, China","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100578688","immune-checkpoint-inhibitors-icis-retreatment-in-second-line-treatment-of-advanced-gastric-cancer-a-retrospective-real-world-study-100578688","NCT06814548","Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study","Inclusion Criteria:\n\n* Histologically confirmed metastatic or advanced GC\u002FGEJC;\n* Received at least 2 cycles of anti-PD-1 or PD-L1 based therapy in the first-line setting;\n* Receiving at least 2 cycles of ICI-based second-line therapy;\n* ECOG PS 0 or 1;\n* Radiographic response was also assessed during treatment and survival.\n\nExclusion Criteria:\n\n* patients had other malignancies within the past 5 years;\n* lack of survival and clinical efficacy data;\n* combined radiotherapy regimens in the second-line treatment.",{"count":51,"type":21},200,"OBSERVATIONAL","This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.",[27,55,56,57],"Immune Checkpoint Inhibitors (ICIs)","Second-line","Retreatment","NOT_YET_RECRUITING","2025-02-03",{"date":61,"type":35},"2025-02-07",{"date":63,"type":21},"2025-02-10",{"date":65,"type":21},"2025-05-31",{"name":67,"class":42},"Yongxu Jia",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100576505","the-relationship-of-psychological-stress-with-therapy-efficacy-and-prognosis-of-gastric-cancer-100576505","NCT06786169","The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer","Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer (G-STRESS)","Cohort 1\n\nInclusion Criteria:\n\n1. Lower age limit of research subjects 18 years old and upper age limit of 80 years old, ECOG (ECOG score standard) performance status of 0 or 1\n2. Be proven to be primary adenocarcinoma of gastric cancer and staged II-III by pathological evidences\n3. R0 gastrectomy with D2 lymphadenectomy\n4. Receiving adjuvant chemotherapy\n\nExclusion Criteria:\n\n1. History of chemotherapy, radiotherapy, immunotherapy or target therapy\n2. Multiple primary tumors\n3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases\n4. Unavailable for R0 resection and D2 lymph node dissection.\n5. Patients with stage IV gastric cancer\n\nCohort 2\n\nInclusion Criteria:\n\n1. Lower age limit of research subjects 18 years old and upper age limit of 80 years old, ECOG (ECOG score standard) performance status of 0 or 1\n2. Be proven to be primary adenocarcinoma of gastric cancer and staged III-IV by pathological evidences\n3. Receiving gastrectomy\n4. Receiving preoperative chemotherapy\n\nExclusion Criteria:\n\n1. Unavailable for chemotherapy, radiotherapy, immunotherapy or target therapy\n2. Multiple primary tumors\n3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases\n4. Unavailable for gastrectomy\n\nCohort 2\n\nInclusion Criteria:\n\n1. Lower age limit of research subjects 18 years old and upper age limit of 80 years old, ECOG (ECOG score standard) performance status of 0 or 1\n2. Be proven to be primary adenocarcinoma of gastric cancer and staged IV by pathological evidences\n3. Unavailable for gastrectomy\n4. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors version 1.1\n\nExclusion Criteria:\n\n1. Unavailable for chemotherapy, radiotherapy, immunotherapy or target therapy\n2. Multiple primary tumors\n3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases","80 Years",{"count":77,"type":21},600,"This is the prospective, observational cohort study (G-Distress) to explore the associations of psychological stress with treatment and prognosis of gastric cancer. The participants including the patients diagnosed with gastric cancer who received surgery, chemotherapy and immune checkpoint inhibitors.",[27],[81,82],"Gastric Cancer","Stress","2025-01-21",{"date":85,"type":35},"2025-01-22",{"date":87,"type":35},"2024-09-05",{"date":89,"type":21},"2029-09-15",{"name":91,"class":42},"Fudan University",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":100,"targetDuration":102,"studyType":52,"phases":4,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":43},"100574559","a-prospective-cohort-study-on-the-treatment-of-locally-advanced-gastric-cancer-100574559","NCT06760858","A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer with SOX Plus Tislelizumab Combined with HIPEC","Inclusion Criteria:\n\n* Patients with newly diagnosed Her-2 negative gastric adenocarcinoma, with no prior chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.\n* Age between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.\n* Staging according to the American Joint Committee on Cancer (AJCC) 8th edition is T4aNxM0, without obstruction, perforation, or bleeding risk.\n* Good bone marrow reserve function, with the following blood criteria: white blood cell count ≥3×10\\^9\u002FL, neutrophils ≥1.5×10\\^9\u002FL, platelet count ≥100×10\\^9\u002FL, hemoglobin ≥90 g\u002FL.\n* Good organ function, with the following biochemical criteria: aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), alanine aminotransferase (ALT) ≤2.5×ULN, serum total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL\u002Fmin.\n* International normalized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.\n* Urine protein \\\u003C2+, if urine protein ≥2+ then 24-hour urine protein quantification must be ≤1g.\n* Consent to provide blood and tissue samples.\n* Expected survival of more than 3 months.\n* Female subjects agree to strict contraception; male subjects with partners of childbearing potential agree to use effective contraception during the study period.\n* Voluntarily sign the informed consent form, willing and able to comply with planned visits, study treatments, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n* Participants who have been enrolled in any other drug clinical trial or have participated in any drug clinical trial within the last month.\n* Any anti-cancer treatments (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than the study medication (palliative external beam radiation for non-target lesions is allowed).\n* Prior use of similar chemotherapy drugs or immune checkpoint inhibitors.\n* Presence of metastatic lesions in the liver, lungs, para-aortic lymph nodes, bones, brain, adrenal glands, or pelvic and abdominal cavity.\n* Gastrointestinal perforation, obstruction, or uncontrollable diarrhea within 6 months prior to enrollment.\n* Other untreated or concurrent tumors, except for cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors. Patients with tumors that have been cured and have no evidence of disease for more than 5 years may be included. All other tumors must have been treated at least 5 years prior to enrollment.\n* Symptomatic meningiomas：\n* History of active autoimmune diseases or refractory autoimmune diseases.\n* Received corticosteroids (\\>10mg\u002Fday prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days prior to enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg\u002Fday); local steroid therapy; and short-term prophylactic steroid therapy for allergies or nausea and vomiting.\n* History of HIV infection or active hepatitis B\u002FC virus infection.\n* Persistent \\> Grade 2 bacterial, fungal, viral infections.\n* Active or clinically significant cardiac disease:\n* Congestive heart failure \\> New York Heart Association (NYHA) Class II;\n* Active coronary artery disease;\n* Arrhythmias requiring treatment other than beta-blockers or digoxin;\n* Unstable angina (angina symptoms at rest), new-onset angina within 3 months prior to enrollment, or unhealed wounds, ulcers, or fractures due to myocardial infarction within 6 months prior to enrollment.\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis.\n* Patients requiring medication for epilepsy.\n* History of organ transplantation (including corneal transplants).\n* Allergy to the study medication or similar drugs, or suspected allergies.\n* Pregnant or breastfeeding women.\n* Major surgery, open biopsy, or significant traumatic surgery within 4 weeks prior to recruitment.\n* History of vaccination within 4 weeks prior to enrollment.\n* Patients deemed unsuitable for the study by the investigator.",{"count":101,"type":21},122,"3 Years","The clinical trial aims to assess the efficacy and safety of Tislelizumab combined with the SOX regimen and HIPEC in treating locally advanced gastric cancer. The primary and secondary objectives are as follows:\n\nTo evaluate the 3-year disease-free survival (DFS) in patients with locally advanced gastric cancer treated with systemic SOX chemotherapy plus Tislelizumab and HIPEC.\n\nTo assess the major pathological response (MPR) in these patients. Secondary objectives include safety, pathological complete response (pCR), progression-free survival (PFS), tumor regression grade (TRG), overall survival (OS), incidence of adverse reactions during treatment, postoperative adverse reactions, and treatment efficacy.\n\nParticipants will:\n\nBe willing to receive SOX plus Tislelizumab combined with HIPEC treatment (exposure group), undergo HIPEC followed by SOX and Tislelizumab to achieve stable disease (SD), partial response (PR), or complete response (CR). Patients who can undergo surgery after the second exploration will receive surgery and HIPEC treatment. If surgery is not possible, a multidisciplinary team (MDT) discussion will follow to determine the next treatment plan. Patients with progressive disease (PD) will also have an MDT discussion to determine the subsequent treatment.\n\nBe willing to receive SOX combined with HIPEC treatment (observation group), undergo HIPEC followed by SOX to achieve SD, PR, or CR. Patients who can undergo surgery after the second exploration will receive surgery and HIPEC treatment. If surgery is not possible, an MDT discussion will follow to determine the next treatment plan. Patients with PD will also have an MDT discussion to determine the subsequent treatment.\n\nTreatment details:\n\nSOX: S-1 dosage based on body surface area (BSA): \\\u003C1.25m², 40 mg bid orally, 1.25-1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg\u002Fm² IV day 1, for a total of 3 cycles.\n\nTislelizumab: 200mg IV, day 1, Q3W, for a total of 3 cycles. HIPEC: Docetaxel: 120mg, day 1, day 3.",[27],[106],"neoadjuvant chemotherapy","2025-01-06",{"date":109,"type":35},"2025-01-07",{"date":111,"type":35},"2024-12-01",{"date":113,"type":21},"2029-09-01",{"name":41,"class":42},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":123,"targetDuration":102,"studyType":52,"phases":4,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":92},"100566971","immune-proteomics-to-predict-neoadjuvant-chemotherapy-and-immunotherapy-response-in-gastric-cancer-100566971","NCT06662110","IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer","A Prospective Cohort Study on Serum Immune Protein Signature for Predicting Neoadjuvant Therapy Efficacy in Advanced Gastric Cancer","IMPACT-GC","Inclusion Criteria\n\n1. Males or females aged 18 to 75 years;\n2. Newly diagnosed histologically confirmed gastric adenocarcinoma;\n3. Lesion located in the stomach or gastroesophageal junction as assessed by endoscopic ultrasound and enhanced CT, with clinical staging of T3-4NxM0 (based on the 8th edition of AJCC TNM classification);\n4. Determined suitable for neoadjuvant chemotherapy or neoadjuvant chemotherapy combined with immunotherapy after multidisciplinary consultation, with potential for curative resection post-treatment. The chemotherapy regimen is restricted to fluoropyrimidine and platinum-based systemic chemotherapy; the immunotherapy regimen is restricted to immune checkpoint inhibitors.\n\nExclusion Criteria\n\n1. Prior receipt of any anti-tumor therapy for current gastric cancer or receipt of anti-tumor drugs for other conditions within the past 4 weeks;\n2. Presence of another malignancy or multiple primary tumors;\n3. Serious comorbidities with a life expectancy of less than 5 years;\n4. Severe chronic or active infections requiring systemic anti-infective therapy;\n5. Blood transfusion within the past week;\n6. Receipt of corticosteroid or immunosuppressive therapy within the past 2 weeks;\n7. Administration of a live vaccine within the past 4 weeks.",{"count":124,"type":21},206,"The overall efficacy of neoadjuvant treatment for advanced gastric cancer is limited due to significant heterogeneity in patient responses. While neoadjuvant therapy offers hope for improved clinical outcomes, the key challenge is accurately predicting individual treatment responses. Identifying reliable biomarkers to guide treatment decisions is therefore critical. Immune factors are pivotal in the efficacy of gastric cancer treatment, but most research has predominantly focused on the tumor immune microenvironment. This study aims to validate the predictive value of systemic immune markers in predicting neoadjuvant treatment responses in advanced gastric cancer.\n\nBuilding on our previous research, where we established a retrospective cohort of patients with advanced gastric cancer undergoing preoperative chemotherapy, we employed a novel serum proteomics platform based on proximity extension assays (PEA) to measure key immune protein levels in patient serum. This led to the development of the PSRscore system, a serum immune protein score that effectively predicted tumor regression after preoperative chemotherapy (published in Cell Reports Medicine, doi: 10.1016\u002Fj.xcrm.2023.100931).\n\nIn this prospective cohort study, we will enroll 166 patients with resectable advanced gastric cancer undergoing neoadjuvant chemotherapy. Baseline serum samples will be collected prior to treatment, and the PSRscore will be used to predict tumor regression. Pathological evaluation post-chemotherapy will confirm tumor response, helping to further validate and refine the PSRscore system. Additionally, an exploratory cohort of 40 patients receiving combined neoadjuvant chemotherapy and immunotherapy will be included to evaluate the correlation between PSRscore and clinical benefit from immunotherapy.\n\nThis research is expected to lead to the development of a predictive diagnostic kit based on the PSRscore for advanced gastric cancer patients undergoing neoadjuvant therapy, with the ultimate goal of improving clinical decision-making and enhancing treatment outcomes for gastric cancer patients.",[27],"2024-10-25",{"date":129,"type":35},"2024-10-28",{"date":131,"type":35},"2024-08-01",{"date":133,"type":21},"2029-06-30",{"name":135,"class":42},"Shanghai Zhongshan Hospital"]